XML 43 R21.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Information
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Segment Information Segment Information
The Company has determined that it operates in a single reportable segment, which is the research and development of innovative drug candidates for the treatment of human cancer. Resources are allocated and performance is assessed by the Company's President and Chief Executive Officer, whom the Company has determined to be its Chief Operating Decision Maker (CODM).
The CODM considers actual operating results on an annual basis on a consolidated basis, including consolidated net loss, when making decisions about allocating capital and personnel to the segment in the annual budgeting and forecasting process, which includes comparison of budget to actual and current period to prior period variances. The CODM assesses performance for the operating segment and decides, in part, how to allocate resources based on net loss that also is reported on the Consolidated Statement of Operations as net loss. The measure of segment assets is reported on the Consolidated Balance Sheets as total assets.
In addition to the significant categories included within net loss presented on the Company's Consolidated Statement of Operations, the following table is representative of the significant expense categories for the years ended December 31, 2024 and 2023, including a reconciliation to Net Loss:
For the Year Ended
December 31,
20242023
Revenues, net$10,908 $10,023 
Direct research and development expenses22,246 23,078 
Research and development employee related costs14,499 14,330 
General and administrative employee related costs8,722 9,171 
Professional, legal, and consulting costs4,810 5,598 
Other segment items (1)
4,020 5,259 
Net loss$(43,389)$(47,413)
(1) Other operating expenses for the reportable segment includes cost of royalties, facility related costs, insurance costs